# A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Source: https://onco.cc/trials/nct04256317/  
OnCo record `nct04256317` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Azacitidine and Venetoclax in myelodysplastic syndromes / neoplasms, acute myeloid leukaemia and chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, run by Taiho Oncology, Inc., now recruiting.

## Summary

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) is a phase 2/3 interventional study registered as NCT04256317 by Taiho Oncology, Inc., with 316 participants planned, started 2020-05-21 and due to reach its primary completion in 2027-11-01. Interventions recorded: Azacitidine, ASTX030 (cedazuridine + azacitidine), Cedazuridine and Venetoclax.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04256317
- Phase: 2/3
- Setting: A Multi-phase, Pharmacokinetics, Safety, and Efficacy Study of ASTX030 (Azacitidine and Cedazuridine) as Monotherapy in Subjects With Myeloid Neoplasm or in Combination With Venetoclax in Subjects With AML (AZTOUND Study)
- Sponsor: Taiho Oncology, Inc.
- Enrolled: 316

## Sources

- ClinicalTrials.gov NCT04256317: https://clinicaltrials.gov/study/NCT04256317

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms](https://onco.cc/cancers/cmml/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- drugs: [Azacitidine](https://onco.cc/drugs/azacitidine/), [Venetoclax](https://onco.cc/drugs/venetoclax/)
- companies: [Araris Biotech (Taiho)](https://onco.cc/companies/araris/)

---
JSON: https://onco.cc/api/v1/entities/nct04256317.json